Overview
IBIO market data
Price History
IBIO price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$1.75 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.25 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -3,049.4% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $0.57 – $3.82 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $73M · P/B 0.67 · P/S 146.06.
Company News
8-K filing — iBio, Inc. (IBIO)SEC EDGAR · Aug 4, 2026, 11:05 AM
iBio Announces New Preclinical Data From Obese Non-Human Primate Study Evaluating IBIO-610, Activin E Antibody CandidateBenzinga · Jul 1, 2026, 11:15 AM
Raymond James Initiates Coverage On iBio with Outperform Rating, Announces Price Target of $5Benzinga · Jun 8, 2026, 6:00 PM
iBio Begins Human Testing of Obesity Drug Candidate, First Patient Dosed in Company's Initial Clinical TrialBenzinga · Jun 2, 2026, 11:05 AM